Comparative Study on Efficacy of Myoinositol over Metformin in Polycystic Ovary Syndrome Patients

Introduction: Polycystic ovarian syndrome (PCOS) is the most common endocrine disorder in women of reproductive age, prevalent across different populations around the world. PCOS prevalence worldwide is estimated to be 6-10% or even 15% when the diagnosis is based on Rotterdam criteria. Studies of PCOS in India carried out in convenience samples reported a prevalence of 3.7% to 22.5%, with 9.13% to 36% prevalence in adolescents only.Materials and Methods: A study during January 2020 to December 2020 was done on patients attending the department of Gynaecology& Obstetrics of Govt Medical College, Ananthapur. A total of 50 women with PCOS and infertility were selected and their reports generated according to Rotterdam classification. Out of 50 patients 25 were recommended Myoinositol 2000 mg thrice a day and Folic acid 200 μg twice a day and continued for at least 3 months. Another 25 patients were treated with Metformin 1500 mg/ day in three divided dosages.Results: The data of 50 women with PCOS were evaluated. Baseline characteristic like age and BMI were almost similar in both groups. According to obtained records, 37 women experienced an improvement of their menstrual cycle towards ovulatory cycles. A total number of 13 women became pregnant. This result could be achieved in the form of pregnancy after the intake of 2-3 months of Myoinositol and Folic acid. No relevant side effects were reported in the patients taking Myoinositol and Folic acid.Conclusion: This confirms that myoinositol is not only an effective alternative in the treatment of PCOS patients but also a safe and secure drug as no side effects could be observed in the standard dosages. On the other side easy compliance results in the better outcome in the management of ovulation, hyperandrogenism and metabolic parameters on patients with PCOS